文献速递乳腺癌消化系统肿瘤胸部肿瘤

抗体偶联药物:跨肿瘤组织学类型的智能化疗递送

Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies.
PubMed 文献 · CA Cancer J Clin · 2021-11-12

本文综述了美国食品药品监督管理局已批准用于实体瘤的抗体偶联药物(ADC),重点讨论基于分子标志物而非组织来源的跨组织学扩展。文章以抗HER2 ADC德曲妥珠单抗为例,说明其在HER2过表达的乳腺癌、胃癌、结直肠癌和肺癌中显示活性,并提及Trop-2和nectin-4等潜在跨组织学靶点,最后讨论多组织学扩展带来的挑战与机遇。

要点

  • 多种组织学无关疗法已用于临床,ADC正基于表面靶点跨肿瘤类型进行评估。
  • 抗HER2 ADC德曲妥珠单抗在HER2过表达的乳腺癌、胃癌、结直肠癌和肺癌中显示活性。
  • Trop-2和nectin-4等是新型潜在跨组织学ADC靶点。

核心结论

  • 随着表面靶点在多种癌症组织学中表达的认识以及现代ADC的显著活性,ADC类药物正被越来越多地评估为适合跨组织学扩展适应症。

研究设计与样本

  • 本文为综述,总结美国食品药品监督管理局对实体瘤的ADC批准情况,并讨论ADC多组织学扩展的挑战与机遇。

主要发现

  • 抗HER2 ADC德曲妥珠单抗在HER2过表达的乳腺癌、胃癌、结直肠癌和肺癌中显示出引人注目的活性。
  • 其他新型潜在跨组织学ADC靶点包括滋养层细胞表面抗原2(Trop-2)和nectin-4等。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As distinct cancer biomarkers have been discovered in recent years, a need to reclassify tumors by more than their histology has been proposed, and therapies are now tailored to treat cancers based on specific molecular aberrations and immunologic markers. In fact, multiple histology-agnostic therapies are currently adopted in clinical practice for treating patients regardless of their tumor site of origin. In parallel with this new model for drug development, in the past few years, several novel antibody-drug conjugates (ADCs) have been approved to treat solid tumors, benefiting from engineering improvements in the conjugation process and the introduction of novel linkers and payloads. With the recognition that numerous surface targets are expressed across various cancer histologies, alongside the remarkable activity of modern ADCs, this drug class has been increasingly evaluated as suitable for a histology-agnostic expansion of indication. For illustration, the anti-HER2 ADC trastuzumab deruxtecan has demonstrated compelling activity in HER2-overexpressing breast, gastric, colorectal, and lung cancer. Examples of additional novel and potentially histology-agnostic ADC targets include trophoblast cell-surface antigen 2 (Trop-2) and nectin-4, among others. In the current review article, the authors summarize the current approvals of ADCs by the US Food and Drug Administration focusing on solid tumors and discuss the challenges and opportunities posed by the multihistological expansion of ADCs.

来源:CA Cancer J Clin,查看原文。版权归原作者所有。

引用

  1. Tarantino P, Carmagnani Pestana R, Corti C, et al. Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies. CA Cancer J Clin. 2021. PMID: 34767258. doi:10.3322/caac.21705

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。